Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
Feng ZhangWenfeng LiuFansheng MengQiuyu JiangWenqing TangZhiyong LiuXiahui LinRuyi XueSi ZhangLing DongPublished in: Journal for immunotherapy of cancer (2024)
Macrophage-specific PLA2G7 serves as a novel biomarker capable of prognosticating immunotherapy responsiveness and inhibiting PLA2G7 has the potential to enhance the efficacy of ICB therapy for HCC.